UK/Europe regulatory headwinds intensify: NHS contract under review, OSR compliance questions, open-source rival, France/Germany rival pledge; FT study challenges effectiveness; ChapsVision emerges as concrete challenger; Karp warns against Europe regulation
Key Questions
What is the status of Palantir's NHS contract?
The NHS contract is under review with an exit decision expected by autumn. OSR compliance questions require stronger caveats on effectiveness claims.
What did the FT study find about Palantir's NHS tool?
The study concluded Palantir's tool has not reduced hospital discharge delays, directly challenging marketing claims about its effectiveness.
How are European governments responding to Palantir?
France and Germany pledged to develop a joint Palantir rival, while an ex-GCHQ chief called for a British alternative amid data sovereignty concerns.
What is the open-source rival to Palantir in Europe?
World Monitor on GitHub is emerging as a competitive open-source alternative, increasing pressure on Palantir's position.
What public opinion exists on Palantir's NHS role?
A YouGov poll showed 65% of respondents want the NHS contract dropped.
What regulatory action has the UK stats watchdog taken?
The watchdog instructed NHS England to add stronger caveats to Palantir-related claims following a probe into effectiveness data.
How has the Met Police contract with Palantir been affected?
The Met Police blocked a trial originally set for January 2027 amid the broader regulatory scrutiny.
Who is ChapsVision and why does it matter for Palantir?
ChapsVision is a French challenger using a roll-up strategy with DGSI contracts and interest from Germany and Poland, representing a concrete European sovereignty threat.
NHS contract under review with exit decision by autumn. OSR probe findings require stronger caveats. YouGov poll: 65% want contract dropped. Met Police block trial set Jan 2027. France/Germany jointly pledge rival. FT study finds Palantir's tool has not cut hospital discharge delays; Health Foundation finding reinforces this, and NHS now requests independent review. French PM announced via Instagram seeking divorce from Palantir, opening doors for ChapsVision. Bloomberg piece details French challenger ChapsVision (roll-up, DGSI contract, Germany/Poland interest). Karp warns US against Europe's AI regulation path, urges no ban on open models; cites 'token maxed' customer frustration as sign of AI adoption friction. FOI release confirms no Palantir contracts in Scotland in last 5 years, adding to UK headwinds. New: NHS England faces backlash over Palantir's access to patient data; breach of data access assurances reported; National Data Guardian investigating. This deepens reputational and regulatory risk.